These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15617340)

  • 1. [Recombinant AAV-LMP-induced LMP specific cytotoxic response to autologous lymphoblastoid cell lines tranformed by Epstein-Barr virus].
    Zhao F; Liu H; Zhou L; Cai W; Du B; Ye S; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):247-51. PubMed ID: 15617340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant adeno-associated virus mediated RNA interference inhibits metastasis of nasopharyngeal cancer cells in vivo and in vitro by suppression of Epstein-Barr virus encoded LMP-1.
    Li X; Liu X; Li CY; Ding Y; Chau D; Li G; Kung HF; Lin MC; Peng Y
    Int J Oncol; 2006 Sep; 29(3):595-603. PubMed ID: 16865275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
    Delecluse HJ; Feederle R; Behrends U; Mautner J
    Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
    Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
    Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
    Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dendritic cells transfected with recombinant adenovirus Ad5F35-LMP2 induces LMP2 specific immunity mediated by cytotoxic T lymphocytes in vitro].
    Mo WN; Zhou L; Wang Z; Tang AZ; Huang GW; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Aug; 22(4):254-6. PubMed ID: 19105335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
    J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.
    Moss DJ; Misko IS; Burrows SR; Burman K; McCarthy R; Sculley TB
    Nature; 1988 Feb; 331(6158):719-21. PubMed ID: 2830541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of rAAV-mediated RNA interference against EB virus-encoded latent membrane protein 1 on nasopharyngeal carcinoma cell proliferation and metastasis in nude mice].
    Liu X; Liu X; Li G; Zhang B; Wang L; Li XH; Li XP
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):611-4. PubMed ID: 19403376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
    Ding W; Fong C
    Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones.
    Honda S; Takasaki T; Okuno K; Yasutomi M; Kurane I
    Acta Virol; 1998 Nov; 42(5):307-13. PubMed ID: 10358731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
    Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
    J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.